Acadia Pharmaceuticals (ACAD) Enterprise Value (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Enterprise Value of -$851.5 million for Q1 2026, down 24.92% year-over-year from -$1.1 billion in Q1 2025, and down 3.88% quarter-over-quarter from -$819.7 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Enterprise Value (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$851.5 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 24.92% year-over-year to -$851.5 million; the TTM figure through Mar 2026 stood at -$851.5 million (down 24.92% YoY), while the FY2025 annual figure was -$819.7 million, down 8.43% from the prior year.
- Enterprise Value for Q1 2026 stood at -$851.5 million, down from -$819.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$345.9 million in Q3 2023, with the low at -$851.5 million in Q1 2026.
- The 5-year median for Enterprise Value is -$470.5 million (2024), against an average of -$562.0 million.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value increased 22.81% in 2022, then slumped 72.26% in 2024.
- Acadia Pharmaceuticals' Enterprise Value stood at -$416.8 million in 2022, then retreated by 5.29% to -$438.9 million in 2023, then slumped by 72.26% to -$756.0 million in 2024, then slipped by 8.43% to -$819.7 million in 2025, then decreased by 3.88% to -$851.5 million in 2026.
- Business Quant data shows ACAD's Enterprise Value at -$851.5 million in Q1 2026, -$819.7 million in Q4 2025, and -$847.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | -956.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -956.47 Mn |
| Mar 31, 2026 | -851.46 Mn |
| Dec 31, 2025 | -819.69 Mn |
| Sep 30, 2025 | -847.02 Mn |
| Jun 30, 2025 | -762.00 Mn |
| Mar 31, 2025 | -681.58 Mn |
| Dec 31, 2024 | -755.99 Mn |
| Sep 30, 2024 | -565.33 Mn |
| Jun 30, 2024 | -500.94 Mn |
| Mar 31, 2024 | -470.52 Mn |
| Dec 31, 2023 | -438.87 Mn |
| Sep 30, 2023 | -345.92 Mn |
| Jun 30, 2023 | -375.38 Mn |
| Mar 31, 2023 | -402.87 Mn |
| Dec 31, 2022 | -416.82 Mn |
| Sep 30, 2022 | -436.58 Mn |
| Jun 30, 2022 | -436.35 Mn |
| Mar 31, 2022 | -445.98 Mn |
| Dec 31, 2021 | -520.71 Mn |
| Sep 30, 2021 | -540.29 Mn |